
ALT Three panels, left to right: (L) Stage view of AffyImmune Therapeutics' President and Chief Operating Officer Matt Britz accepting Scrip's Best Oncology R&D Advance Award for AIC100 ICAM-1 Targeting CAR T Cell Therapy at the 19th Annual Scrip Awards in London, UK. (M) Best Oncology R&D Advance Award trophy - a silver DNA strand on a black base with silver plate and black engraving reading "Scrip Awards 2023 | Best Oncology R&D Advance Award | AffyImmune Therapeutics | ICAM-1 Targeting CAR T Cell Therapy" (R) President and COO Matt Britz poses with the award.

ALT Slide with presentation information for Affy COO Matt Britz's Meeting on the Mesa presentation at 5 pm Pacific time on October 10 in the Rentschler ATMP Ballroom at Park Hyatt Aviara. Slide includes a headshot of Matt Brtiz, the Affy and ARM Meeting on the Mesa logos, and the presentation information.

ALT Cornell Center for Technology Licensing tweet about AffyImmune's early clinical data presented at ASCO 2023 showcased on a Times Square billboard the week of 31 July. The tweet reads "AIC100, an investigational CAR T therapy, developed by @Cornell startup @affyimmune shows promising results in treating anaplastic (ATC) and poorly differentiated (PDTC) thyroid cancers."




















